Cachexia is a
metabolic syndrome consisting of massive loss of muscle mass and function that has a severe impact on the quality of life and survival of
cancer patients. Up to 20% of
lung cancer patients and up to 80% of
pancreatic cancer patients are diagnosed with
cachexia, leading to death in 20% of them. The main drivers of
cachexia are
cytokines such as
interleukin-6 (IL-6),
tumor necrosis factor-alpha (TNF-α),
macrophage inhibitory cytokine 1 (MIC-1/GDF15) and
transforming growth factor-beta (TGF-β). Besides its double-edged role as a
tumor suppressor and activator, TGF-β causes muscle loss through
myostatin-based signaling, involved in the reduction in
protein synthesis and enhanced protein degradation. Additionally, TGF-β induces
inhibin and
activin, causing
weight loss and muscle depletion, while MIC-1/GDF15, a member of the TGF-β superfamily, leads to
anorexia and so, indirectly, to muscle wasting, acting on the hypothalamus center. Against this background, the blockade of TGF-β is tested as a potential mechanism to revert
cachexia, and
antibodies against TGF-β reduced weight and muscle loss in murine models of
pancreatic cancer. This article reviews the role of the TGF-β pathway and to a minor extent of other molecules including
microRNA in
cancer onset and progression with a special focus on their involvement in
cachexia, to enlighten whether TGF-β and such other players could be potential targets for
therapy.